<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02986568</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1616</org_study_id>
    <nct_id>NCT02986568</nct_id>
  </id_info>
  <brief_title>Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers</brief_title>
  <acronym>FUSION IV</acronym>
  <official_title>Cohort Study for Comparing the Efficacy Between the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers (FUSION Trial IV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare standard treatment and fusion ontogenetic surgery
      (total mesometrial resection, laterally extended endopelvic resection, peritoneal mesometrial
      resection) for gynecologic cancer in order to evaluate treatment response, adverse effect and
      survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fujii method and ontogenetic surgery are the surgical method of radical hysterectomy that can
      preserve pelvic organ function as much as possible.

      Fujii method has advantage of preserving pelvic autonomic nerve with radical resection of
      tissue under parametrium. And ontogenetic surgery has advantage of reducing need of radiation
      therapy by radical resection of tissue above parametrium.

      This study is prospective study for fusion ontogenetic surgery that has the advantage of both
      Fujji method and ontogenetic surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative complications</measure>
    <time_frame>Intraoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute complications related with surgery</measure>
    <time_frame>Average 10 days after surgery.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Chronic complications related with surgery</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>lymphocele, lymphedema, thrombosis, infection, etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time period for recovering normal voiding function</measure>
    <time_frame>postoperative (up to 6 month)</time_frame>
    <description>Check residual urine. Keep CIC until residual urine &lt; 100cc</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Uterine Cancer</condition>
  <arm_group>
    <arm_group_label>Ontogenetic surgery - Early cervical cacner</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cervical cancer patients, FIGO stage IB1-IIA2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ontogenetic surgery - Advanced cervical cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cervical cancer patients, FIGO stage IIB- IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ontogenetic surgery - Uterine cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uterine cancer patients, FIGO stage IA, grade3, IB-IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment- Early cervical cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cervical cancer patients, FIGO stage IB1-IIA2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment - Advanced cervical cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cervical cancer patients, FIGO stage IIB- IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment - Uterine cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Uterine cancer patients, FIGO stage IA grade3, IB-IVA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles)</description>
    <arm_group_label>Ontogenetic surgery - Early cervical cacner</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Before surgery, neoadjuvant chemotherapy with cisplatin (40mg/m2 on day 1 of each 7 day cycle for 5 cycles) is performed.</description>
    <arm_group_label>Ontogenetic surgery - Advanced cervical cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peritoneal mesometrial resection</intervention_name>
    <description>Perform Fusion Peritoneal mesometrial resection (PMMR).</description>
    <arm_group_label>Ontogenetic surgery - Uterine cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical hysterectomy</intervention_name>
    <description>Type C radical hysterectomy.</description>
    <arm_group_label>Standard treatment- Early cervical cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent chemoradiation therapy (CCRT)</intervention_name>
    <description>Radiotherapy with Cisplatin 40mg/m2 on day 1 of each 7 day cycle</description>
    <arm_group_label>Standard treatment - Advanced cervical cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laterally extended endopelvic resection, Total mesometrial resection</intervention_name>
    <description>After neoadjuvant chemotherapy, if pelvic wall invasion is absent, perform Fusion Total mesometrial resection (TMMR).
If pelvic wall invasion is present, perform Fusion Laterally extended endopelvic resection (LEER) with preserving bladder, rectum and anus.</description>
    <arm_group_label>Ontogenetic surgery - Advanced cervical cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total mesometrial resection</intervention_name>
    <description>If tumor size &lt; 5cm, perform Fusion Total mesometrial resection (TMMR)
If tumor sized ≥ 5cm, perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above.</description>
    <arm_group_label>Ontogenetic surgery - Early cervical cacner</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil, Cisplatin</intervention_name>
    <description>After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy with 5-fluorouracil and cisplatin. (5-fluorouracil 1000mg/m2 on day 1-5 and Cisplatin 60mg/m2 on day 1 of each 21 day cycle)
If not, no adjuvant therapy.</description>
    <arm_group_label>Ontogenetic surgery - Early cervical cacner</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil, Cisplatin</intervention_name>
    <description>After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy with 5-fluorouracil and cisplatin. (5-fluorouracil 1000mg/m2 on day 1-5 and Cisplatin 60mg/m2 on day 1 of each 21 day cycle)
If not, no adjuvant therapy.</description>
    <arm_group_label>Ontogenetic surgery - Advanced cervical cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin, Cisplatin</intervention_name>
    <description>After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy with doxorubicin and cisplatin. (Doxorubin 60mg/m2 and Cisplatin 50mg/m2 on day 1 of each 21 day cycle)
If not, no adjuvant therapy.</description>
    <arm_group_label>Ontogenetic surgery - Uterine cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Staging operation</intervention_name>
    <description>Perform surgical staging include hysterectomy, bilateral salpingo-oophorectomy, pelvic lymph node dissection and para-aortic lymph node dissection.</description>
    <arm_group_label>Standard treatment - Uterine cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy or Concurrent chemoradiation therapy (CCRT)</intervention_name>
    <description>Undergo adjuvant therapy after surgical staging. Radiotherapy only or CCRT (radiotherapy with Cisplatin 40mg/m2 on day 1 of each 7 day cycle)</description>
    <arm_group_label>Standard treatment - Uterine cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent chemoradiation therapy (CCRT)</intervention_name>
    <description>If risk factor is reported in pathologic report, undergo adjuvant CCRT. (radiotherapy with Cisplatin 40mg/m2 on day 1 of each 7 day cycle)</description>
    <arm_group_label>Standard treatment- Early cervical cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, Age ≥ 20 years

          -  Patients with primary cervical cancer (FIGO stage IB1-IVA)

          -  Patients with primary uterine cancer (FIGO stage IA, grade 3, IB-IVA)

          -  Patients who signed an approved informed consent

        Exclusion Criteria:

          -  Female, Age &lt; 20 years

          -  Patients who refused to sign informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Seung Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hee Seung Kim, MD</last_name>
    <phone>82-2-2072-4863</phone>
    <email>bboddi0311@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seungmee Lee, MD</last_name>
      <phone>82-2-2072-2821</phone>
      <email>yumenoarika@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Hee Seung Kim, MD</last_name>
      <phone>82-2-2072-4863</phone>
      <email>bboddi0311@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hee Seung Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2016</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee Seung Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Ontogenetic surgery</keyword>
  <keyword>TMMR</keyword>
  <keyword>PMMR</keyword>
  <keyword>LEER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

